JP6750941B2 - 精神障害の治療 - Google Patents

精神障害の治療 Download PDF

Info

Publication number
JP6750941B2
JP6750941B2 JP2015535741A JP2015535741A JP6750941B2 JP 6750941 B2 JP6750941 B2 JP 6750941B2 JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015535741 A JP2015535741 A JP 2015535741A JP 6750941 B2 JP6750941 B2 JP 6750941B2
Authority
JP
Japan
Prior art keywords
human
mab
subject
mabp1
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015535741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531396A (ja
JP2015531396A5 (OSRAM
Inventor
シマール，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xbiotech Inc
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of JP2015531396A publication Critical patent/JP2015531396A/ja
Publication of JP2015531396A5 publication Critical patent/JP2015531396A5/ja
Application granted granted Critical
Publication of JP6750941B2 publication Critical patent/JP6750941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
JP2015535741A 2012-10-04 2013-10-01 精神障害の治療 Active JP6750941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
US61/709,741 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020090717A Division JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療

Publications (3)

Publication Number Publication Date
JP2015531396A JP2015531396A (ja) 2015-11-02
JP2015531396A5 JP2015531396A5 (OSRAM) 2016-11-17
JP6750941B2 true JP6750941B2 (ja) 2020-09-02

Family

ID=50435375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015535741A Active JP6750941B2 (ja) 2012-10-04 2013-10-01 精神障害の治療
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Country Status (7)

Country Link
EP (1) EP2903643A4 (OSRAM)
JP (3) JP6750941B2 (OSRAM)
KR (1) KR20150064091A (OSRAM)
CN (1) CN104684581A (OSRAM)
AU (1) AU2013327498B2 (OSRAM)
CA (1) CA2886757C (OSRAM)
WO (1) WO2014055541A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN110382001A (zh) 2017-02-16 2019-10-25 埃克斯生物科技公司 化脓性汗腺炎的治疗
EP4615135A1 (en) 2022-11-04 2025-09-10 Panasonic Intellectual Property Corporation of America Terminal, base station, communication method, and integrated circuit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US8034337B2 (en) * 2008-05-30 2011-10-11 Xbiotech, Inc. Interleukin-1α antibodies
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
DK2694107T3 (en) * 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS

Also Published As

Publication number Publication date
WO2014055541A1 (en) 2014-04-10
JP2015531396A (ja) 2015-11-02
AU2013327498A1 (en) 2015-04-02
EP2903643A1 (en) 2015-08-12
CA2886757C (en) 2022-04-05
AU2013327498B2 (en) 2018-06-28
JP2022177132A (ja) 2022-11-30
CN104684581A (zh) 2015-06-03
EP2903643A4 (en) 2016-06-15
KR20150064091A (ko) 2015-06-10
CA2886757A1 (en) 2014-04-10
JP2020143133A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
US11191831B2 (en) Treatment of psychiatric conditions
JP6453278B2 (ja) 皮膚科的病理の治療
JP6750941B2 (ja) 精神障害の治療
US12116405B2 (en) Arthritis treatment
KR102104296B1 (ko) 종양성 질병들에 대한 치료
HK40013773A (zh) 皮肤病学病状的治疗
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200813

R150 Certificate of patent or registration of utility model

Ref document number: 6750941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250